Stocks Health care EWTX
NASDAQ · Health careEdgewise Therapeutics, Inc. (EWTX)
In fiscal 2025 capital spending exceeded operating cash flow by $144.1M. At September 30, 2026 it held $68.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Edgewise Therapeutics, Inc.
- Net worth
- Edgewise Therapeutics, Inc. has a market value (market cap) of $5.3B at the latest share price, and shareholders' equity of $1.6B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $143.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Edgewise Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Edgewise Therapeutics, Inc. does
Edgewise Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker EWTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$167.8M | -$1.63 | -$144.1M |
| 2024 | n/a | -$133.8M | -$1.45 | -$110.3M |
| 2023 | n/a | -$100.2M | -$1.57 | -$97.7M |
| 2022 | n/a | -$67.6M | -$1.26 | -$58.2M |
| 2021 | n/a | -$42.8M | -$1.14 | -$34.2M |
| 2021 | n/a | -$17.1M | -$23.17 | -$14.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Edgewise Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 4, 2026
- November 4, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026
- August 6, 2026
- July 16, 2026Exhibits 8-K/A
Insider trades
What the people running Edgewise Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $126.7K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Fox Jonathan CDirector | Received as pay | 308 | - |
| August 13, 2026 | Donovan Joanne M.CMO | Soldpre-planned (10b5-1) | 2,919 | $126.7K |
| August 12, 2026 | Koch KevinPresident and CEO, Director | Exercised options | 17,969 | - |
| August 12, 2026 | Koch KevinPresident and CEO, Director | Exercised options | 21,875 | - |
| August 12, 2026 | Koch KevinPresident and CEO, Director | Sold | 8,782 | $383.3K |
| August 12, 2026 | Koch KevinPresident and CEO, Director | Sold | 8,276 | $361.3K |
| August 12, 2026 | Koch KevinPresident and CEO, Director | Sold | 913 | $40.5K |
| August 12, 2026 | Moore John RGeneral Counsel | Exercised options | 5,781 | - |
Who owns EWTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Orbimed Advisors LLC13D, may seek influence with 3 related filers | 14.5% | May 12, 2025 |
| Paradigm BioCapital Advisors LP13G, passive with 3 related filers | 9.5% | August 14, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 7.8% | August 14, 2026 |
| Janus Henderson Group PLC13G, passive | 5.5% | May 15, 2026 |
| Fmr LLC13G, passive with 1 related filers | 5.1% | August 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 225 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Orbimed Advisors LLC | 15,518,492 | 0 |
| Paradigm Biocapital Advisors LP | 10,215,455 | +2,850,417 |
| RA Capital Management, L.P. | 8,392,730 | -2,035,707 |
| BlackRock, Inc. | 6,606,336 | +133,345 |
| Jupiter Topco LLC | 6,075,331 | new |
| Fmr LLC | 5,489,135 | +4,472,083 |
| Novo Holdings A/S | 5,350,000 | 0 |
| Driehaus Capital Management LLC | 4,728,623 | +250,681 |
| Perceptive Advisors LLC | 4,373,974 | -50,000 |
| Vanguard Capital Management LLC | 3,860,670 | +72,509 |
| Baker Bros. Advisors LP | 3,701,719 | -2,874,221 |
| Siren, L.L.C. | 3,184,629 | -1,245,634 |
| Cormorant Asset Management, LP | 2,510,000 | -750,000 |
| Geode Capital Management, LLC | 2,174,051 | +384,232 |
| Integral Health Asset Management, LLC | 2,000,000 | +400,000 |
| Braidwell LP | 1,996,965 | -350,618 |
| Morgan Stanley | 1,948,597 | -297,431 |
| State Street Corp | 1,827,927 | +111,104 |
| Alliancebernstein L.P. | 2,119,024 | +396,855 |
| Mpm Bioimpact LLC | 1,620,780 | -39,916 |
Insiders
7 insiders reported holding 187,063 shares in total, about $9.1M at the last price.
| Holder | Shares |
|---|---|
| Koch KevinPresident and CEO, Director | 52,488 |
| Derakhshan BehradChief Business Officer | 31,826 |
| Russell Alan JChief Scientific Officer, Director | 31,466 |
| Fox Jonathan CDirector | 25,141 |
| Edris BadreddinDirector | 19,820 |
| Moore John RGeneral Counsel | 17,697 |
| Donovan Joanne M.CMO | 8,625 |
Questions about EWTX
What does Edgewise Therapeutics, Inc. do?
Edgewise Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as EWTX. Its shares trade on NASDAQ under the ticker EWTX.
What is Edgewise Therapeutics, Inc.'s net worth?
Edgewise Therapeutics, Inc. has a market value (market cap) of $5.3B at the latest share price, and shareholders' equity of $1.6B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Edgewise Therapeutics, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $1B.
When did Edgewise Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 5, 2026.
When is Edgewise Therapeutics, Inc.'s next earnings report?
Edgewise Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare EWTX with
Follow EWTX
Get an email when Edgewise Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Edgewise Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.